TY - JOUR T1 - Usefulness of new hypoxia PET tests to estimate the prognosis of non-small cell lung cancer JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1395 LP - 1395 VL - 56 IS - supplement 3 AU - Hirofumi Fujii AU - Tomonari Kinoshita AU - Yoshiki Kojima Y1 - 2015/05/01 UR - http://jnm.snmjournals.org/content/56/supplement_3/1395.abstract N2 - 1395 Objectives In addition to the resistance of tumor hypoxic areas to radiotherapy, recent studies revealed that these areas are also biologically more aggressive than normoxic areas, and they can deteriorate the prognosis of tumor-suffering patients. In this study, we investigated if new PET tests to visualize tumor hypoxia would be useful to estimate the prognosis of non-small cell lung cancer patients.Methods Forty-seven patients with non-small cell lung cancer (NSCLC) (male : female = 38:11, age 40-82 yrs old) received two kinds of new hypoxia PET tests before their treatment. Forty-five received 18F-fluoroazomycin arabinoside (FAZA) PET tests, 22 received 62Cu-diacetyl-bis (N4)-methylsemithiocarbazone (ATSM) tests (20 underwent both hypoxia PET tests). After these diagnostic tests, the patients underwent standard therapy; i.e., those with stage IA-IIIA underwent surgery and those with IIIB received radiotherapy or chemoradiotherapy. They were followed up by CT tests, physical examinations and blood tests, and their dates of recurrence and death were recorded.Results With regard to the patients who received these hypoxia PET tests, those with high SUVmax showed significantly poor overall survival and progression-free survival. When optimal cut-off values of SUVmax for 18F-FAZA and 62Cu-ATSM were set to 1.5 and 2.1, p-values for overall survival were 0.001 in 18F-FAZA and 0.041 in 62Cu-ATSM, and p-values for progression-free survival were 0.002 in 18F-FAZA and 0.053 in 62Cu-ATSM.Conclusions Both 18F-FAZA and 62Cu-ATSM PET tests, new hypoxia PET tests, provided useful information on the prognosis of non-small cell lung cancer even when tumors were treated by surgical methods. Our results suggest that broad application of tumor hypoxia PET tests would be expected to estimate the prognosis of patients with non-small cell lung cancer.Research Support This study was partially supported by the Japan Advanced Molecular Imaging Program from Japan Science and Technology Agency. ER -